ERBB2 and breast cancer: The phase 3, randomized DESTINY‐Breast05 study (ClinicalTrials.gov identifier: NCT04622319) investigating T‐DXd versus trastuzumab emtansine (T‐DM1) as adjuvant therapy in patients with HER2‐positive early breast cancer is currently recruiting and may shed light on this issue.